Vés al contingut

Nou estudi per a evitar la metàstasi del càncer de mama

L'IRB Barcelona als mitjans
19 oct. 17

Images

Participants

Contact

Imatge
Communication Officer
Tel.+34 93 40 37255

Una miríada de mitjans nacionals i internacionals s’han fet ressò de l’estudi publicat a Lancet Oncology dirigit por Robert E. Coleman, de la Universitat de Sheffield, que ha comptat amb la participació de Roger Gomis, de l’IRB Barcelona. El treball realitzat permet detectar de manera precoç a les pacients que podrien beneficiar-se de l’àcid zoledrònic i a les que haurien d’evitar-lo. Així, acceleraria l’administració del primer tractament preventiu per a metàstasis.

Enllaç a JANO

Enllaç a La Vanguardia

Enllaç a EFE Futuro

Enllaç a BioTech

Enllaç a Medindia

Enllaç a Medical Xpress

Enllaç a ecancer

Adjunt:
diariomedico.pdf (227.23 KB)

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 28 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).